150 related articles for article (PubMed ID: 34931707)
1. Cumulative risk of a false-positive screening result: A retrospective cohort study using empirical data from 10 biennial screening rounds in BreastScreen Norway.
Tsuruda KM; Larsen M; Román M; Hofvind S
Cancer; 2022 Apr; 128(7):1373-1380. PubMed ID: 34931707
[TBL] [Abstract][Full Text] [Related]
2. The cumulative risk of false-positive results in the Norwegian Breast Cancer Screening Program: updated results.
Roman M; Hubbard RA; Sebuodegard S; Miglioretti DL; Castells X; Hofvind S
Cancer; 2013 Nov; 119(22):3952-8. PubMed ID: 23963877
[TBL] [Abstract][Full Text] [Related]
3. The cumulative risk of false-positive screening results across screening centres in the Norwegian Breast Cancer Screening Program.
Roman M; Skaane P; Hofvind S
Eur J Radiol; 2014 Sep; 83(9):1639-44. PubMed ID: 24972452
[TBL] [Abstract][Full Text] [Related]
4. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study.
Hubbard RA; Kerlikowske K; Flowers CI; Yankaskas BC; Zhu W; Miglioretti DL
Ann Intern Med; 2011 Oct; 155(8):481-92. PubMed ID: 22007042
[TBL] [Abstract][Full Text] [Related]
5. Likelihood of early detection of breast cancer in relation to false-positive risk in life-time mammographic screening: population-based cohort study.
Otten JDM; Fracheboud J; den Heeten GJ; Otto SJ; Holland R; de Koning HJ; Broeders MJM; Verbeek ALM
Ann Oncol; 2013 Oct; 24(10):2501-2506. PubMed ID: 23788759
[TBL] [Abstract][Full Text] [Related]
6. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?
Braithwaite D; Zhu W; Hubbard RA; O'Meara ES; Miglioretti DL; Geller B; Dittus K; Moore D; Wernli KJ; Mandelblatt J; Kerlikowske K;
J Natl Cancer Inst; 2013 Mar; 105(5):334-41. PubMed ID: 23385442
[TBL] [Abstract][Full Text] [Related]
7. Interval Breast Cancer Rates and Histopathologic Tumor Characteristics after False-Positive Findings at Mammography in a Population-based Screening Program.
Hofvind S; Sagstad S; Sebuødegård S; Chen Y; Roman M; Lee CI
Radiology; 2018 Apr; 287(1):58-67. PubMed ID: 29239711
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy.
Kerlikowske K; Zhu W; Hubbard RA; Geller B; Dittus K; Braithwaite D; Wernli KJ; Miglioretti DL; O'Meara ES;
JAMA Intern Med; 2013 May; 173(9):807-16. PubMed ID: 23552817
[TBL] [Abstract][Full Text] [Related]
9. Predictors of re-attendance at biennial screening mammography following a false positive referral: A study among women in the south of the Netherlands.
Voogd AC; Molnar Z; Nederend J; Schipper RJ; Strobbe LJA; Duijm LEM
Breast; 2024 Apr; 74():103702. PubMed ID: 38447293
[TBL] [Abstract][Full Text] [Related]
10. Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age.
O'Meara ES; Zhu W; Hubbard RA; Braithwaite D; Kerlikowske K; Dittus KL; Geller B; Wernli KJ; Miglioretti DL
Cancer; 2013 Nov; 119(22):3959-67. PubMed ID: 24037812
[TBL] [Abstract][Full Text] [Related]
11. Risk of breast cancer after false-positive results in mammographic screening.
Román M; Castells X; Hofvind S; von Euler-Chelpin M
Cancer Med; 2016 Jun; 5(6):1298-306. PubMed ID: 26916154
[TBL] [Abstract][Full Text] [Related]
12. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program.
Hofvind S; Thoresen S; Tretli S
Cancer; 2004 Oct; 101(7):1501-7. PubMed ID: 15378474
[TBL] [Abstract][Full Text] [Related]
13. Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme.
Castells X; Molins E; Macià F
J Epidemiol Community Health; 2006 Apr; 60(4):316-21. PubMed ID: 16537348
[TBL] [Abstract][Full Text] [Related]
14. Participation and cancer detection after reminders versus ordinary invitations in BreastScreen Norway.
Thy JE; Vigeland E; Larsen M; Hofvind S
J Med Screen; 2022 Sep; 29(3):178-184. PubMed ID: 35502849
[TBL] [Abstract][Full Text] [Related]
15. Benefits and Harms of Breast Cancer Screening: A Systematic Review.
Myers ER; Moorman P; Gierisch JM; Havrilesky LJ; Grimm LJ; Ghate S; Davidson B; Mongtomery RC; Crowley MJ; McCrory DC; Kendrick A; Sanders GD
JAMA; 2015 Oct; 314(15):1615-34. PubMed ID: 26501537
[TBL] [Abstract][Full Text] [Related]
16. Mammographic features and risk of breast cancer death among women with invasive screen-detected cancer in BreastScreen Norway 1996-2020.
Moshina N; Backmann HA; Skaane P; Hofvind S
Eur Radiol; 2024 May; 34(5):3364-3374. PubMed ID: 37935848
[TBL] [Abstract][Full Text] [Related]
17. False-positive results in the randomized controlled trial of mammographic screening from age 40 ("Age" trial).
Johns LE; Moss SM;
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2758-64. PubMed ID: 20837718
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Rates of False-Positive and False-Negative Results From Digital Mammography Screening: An Analysis of Registry Data.
Nelson HD; O'Meara ES; Kerlikowske K; Balch S; Miglioretti D
Ann Intern Med; 2016 Feb; 164(4):226-35. PubMed ID: 26756902
[TBL] [Abstract][Full Text] [Related]
19. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
